Navigation Links
REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

SAN MARINO, Calif., Jan. 20 /PRNewswire/ -- Epeius Biotechnologies ( announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37% decrease in tumor size and five patients exhibited disease stabilization with no tumor progression. Importantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 months, and median over-all survival was greater than 9 months.

By direct comparison with a prior low-dose Phase I safety study (Galanis et al. 2008), the new "effective doses" of Rexin-G nearly tripled the overall survival time. Thus, this current Phase I/II study defines a critical pharmacological "threshold" for Rexin-G bioactivity in the treatment of metastatic pancreatic cancer. The present study confirms the overall safety of Rexin-G, and further demonstrates that Rexin-G monotherapy, at these defined dose levels, exhibits profound anti-tumor activity that prolongs both progression-free survival and over-all survival time in pancreatic cancer patients that had previously failed standard chemotherapy.

Rexin-G is the world's first and so far only targeted injectable genetic medicine that has been validated in the clinic (Nature Reviews/Genetics 2007). Injected intravenously, the targeted nanoparticles are designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. The FDA has granted Orphan Drug Status for Rexin-G for the treatment of (i) pancreatic cancer, (ii) osteosarcoma, and (iii) soft tissue sarcoma, while the Philippine BFAD has granted accelerated approval of Rexin-G for the treatment of all solid tumors that are resistant to standard chemotherapy.

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its tumor-targeted gene delivery systems. To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Bio
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
5. Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
8. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
9. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
10. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Post Your Comments:
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)...  An interventional radiology technique shows promise for helping morbidly ... a study being presented today at the annual meeting of ... (RSNA). --> --> ... radiologists as a way to stop bleeding in emergency situations, ... of treating obesity is new. Mubin Syed , ...
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... , November 30, 2015 ... in the development of innovative peptide and gene-based immunotherapeutics ... disease, today announced it will be presenting at the ... December 1, 2015 at 2.30 PM PT. Dr. ... Strategic Advisor will be giving the presentation and will ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
Breaking Biology News(10 mins):